Key takeaways
- A Dutch court ruled that Ceban's compounded semaglutide nasal spray infringed on Novo Nordisk's patent protections.
- Ceban must immediately halt sales, remove listings, disclose its supply chain, and pay Novo Nordisk's legal fees.
- The decision signals an intensifying global legal offensive by brand-name manufacturers against alternative GLP-1 formulations.
- U.S. consumers of compounded semaglutide should expect continued patent litigation from drugmakers as they defend their market.
What happened
In a significant legal victory for brand-name drug manufacturers, Novo Nordisk announced on August 5, 2026, that it secured a preliminary injunction in the Netherlands against Dutch compounding firm Ceban Ziekenhuisfarmacie. A Dutch district court ruled that Ceban's compounded semaglutide nasal spray infringed upon Novo Nordisk’s supplementary protection certificate (SPC) for its proprietary active ingredient.
Why it matters
This European court ruling marks an intensifying global legal crackdown by brand-name pharmaceutical giants against unauthorized compounded formulations of blockbuster GLP-1 medications. For U.S. patients who buy weight-loss medications online, this development highlights the narrowing legal runway for alternative formulations of semaglutide. While the Dutch ruling specifically targeted a nasal spray, it underscores the determination of patent holders to protect their intellectual property against compounding pharmacies that alter the delivery method, dosage, or formulation of semaglutide outside of official patent licensing agreements.
What the data says
The Dutch district court issued several strict mandates against Ceban Compounding B.V. as part of the preliminary injunction, according to the Reuters report:
- Cease Infringing Activities: Ceban must immediately stop manufacturing and distributing its compounded semaglutide nasal spray.
- Remove Product Listings: The compounding pharmacy is required to scrub all commercial listings of the unauthorized product.
- Disclose Supply Chain Details: Ceban must hand over its supply chain information to Novo Nordisk, revealing how the active ingredients were sourced and distributed.
- Financial Penalties: The court ordered Ceban to reimburse Novo Nordisk for its incurred legal expenses.
Semaglutide is the primary active ingredient in Novo Nordisk’s highly profitable, FDA-approved weight-loss injection, Wegovy, and its type 2 diabetes counterpart, Ozempic.
How it compares
For consumers shopping for medical weight-loss solutions, there is a stark divide between brand-name medications and compounded alternatives. Brand-name Wegovy and Eli Lilly’s Zepbound are FDA-approved injections that typically retail for $1,000 to $1,350 per month without insurance. In contrast, patients frequently turn to compounded vs. brand-name semaglutide because compounded options—typically distributed as subcutaneous injections by online telehealth platforms—generally cost between $150 and $400 per month.
Furthermore, while the Dutch case targeted a highly unusual nasal spray formulation, most compounded semaglutide sold in the United States is distributed via traditional subcutaneous injections. Brand-name manufacturers argue that any deviation from their patented formulations raises safety, efficacy, and quality concerns, while compounders argue they are providing essential access during ongoing medication shortages.
How this fits the bigger picture
This European legal victory is not an isolated event; it fits into a broader, highly coordinated legal strategy by both Novo Nordisk and Eli Lilly to shut down unauthorized versions of their star molecules.
We have previously tracked how these pharmaceutical giants have leveraged courtrooms to protect their market share. For instance, in the United States, drugmakers recently managed to defeat an antitrust lawsuit over compounded GLP-1s, which attempted to block brand-name manufacturers from restricting the compounding supply chain. Additionally, as documented in our coverage of surging Zepbound and Mounjaro sales, the soaring commercial demand for these therapies provides an immense financial incentive for manufacturers to aggressively prosecute any entity selling unauthorized, off-patent versions.
What this likely means for U.S. buyers is that compounding pharmacies will face mounting pressure. While the U.S. Food and Drug Administration (FDA) permits compounding during official drug shortages, brand-name manufacturers are actively using patent law, trademark law, and international courts to shut down alternative delivery mechanisms (like nasal sprays or sublingual drops) and prepares the ground to restrict compounded injections the moment official shortages resolve.
What happens next
Following the Dutch court's order, Ceban must comply with the product recalls, supply chain disclosures, and listing removals. Meanwhile, legal experts expect Novo Nordisk to use this European precedent to target other international compounding pharmacies attempting to manufacture non-injectable semaglutide alternatives.
In the United States, the legal status of compounded semaglutide will remain heavily tied to the official FDA shortage database. If you are looking to navigate your options during these shifting legal landscapes, you can consult our directory of telehealth providers or compare pricing and programs directly using our interactive questionnaire.
CompareRx provides factual information and comparison tools for educational purposes. We do not provide medical advice, diagnosis, or treatment.